Medaglia Alice Annalisa, Mancuso Alessandro, Albano Chiara, Zinna Giuseppe, Pipitò Luca, Calà Cinzia, Immordino Rita, Rubino Raffaella, Bonura Silvia, Canino Baldassare, Calamusa Giuseppe, Colomba Claudia, Almasio Pier Luigi, Cascio Antonio
Infectious and Tropical Diseases Unit, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
Antimicrobial Stewardship Team, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
Antibiotics (Basel). 2023 Apr 30;12(5):837. doi: 10.3390/antibiotics12050837.
infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking. The purpose of this study was to determine CDI incidence and risk factors for mortality and recurrence. The "ICD-9 00845" code in hospital-standardized discharged forms (H-SDF) and microbiology datasets were used to retrieve CDI cases at Policlinico Hospital, Palermo between 2013 and 2022. Incidence, ward distribution, recurrence rate, mortality, and coding rate were considered. The risk of death and recurrence was predicted through multivariable analysis. There were 275 CDIs, 75% hospital-acquired, the median time between admission and diagnosis was 13 days, and the median stay was 21 days. Incidence increased from 0.3 to 5.6% (an 18.7-fold increase) throughout the decade. Only 48.1% of cases were coded in H-SDF. The rate of severe/severe-complicated cases increased 1.9 times. Fidaxomicin was used in 17.1% and 24.7% of cases overall and since 2019. Overall and attributable mortalities were 11.3% and 4.7%, respectively. Median time between diagnosis and death was 11 days, and recurrence rate was 4%. Bezlotoxumab was administered in 64% of recurrences. Multivariable analysis revealed that only hemodialysis was associated with mortality. No statistically significant association in predicting recurrence risk emerged. We advocate for CDI notification to become mandatory and recommend coding CDI diagnosis in H-SDF to aid in infection rate monitoring. Maximum attention should be paid to preventing people on hemodialysis from getting CDI.
艰难梭菌感染(CDI)是发病和死亡的重要原因,主要发生在体弱患者中。在意大利,报告并非强制性的,因此缺乏发病率、死亡风险和复发率的数据。本研究的目的是确定CDI的发病率以及死亡和复发的风险因素。利用医院标准化出院表格(H-SDF)中的“ICD-9 00845”代码和微生物学数据集,检索了2013年至2022年期间巴勒莫Policlinico医院的CDI病例。考虑了发病率、病房分布、复发率、死亡率和编码率。通过多变量分析预测死亡和复发风险。共有275例CDI,75%为医院获得性感染,入院至诊断的中位时间为13天,中位住院时间为21天。在这十年间,发病率从0.3%增至5.6%(增长了18.7倍)。H-SDF中仅对48.1%的病例进行了编码。严重/严重复杂病例的比例增加了1.9倍。总体病例中17.1%以及自2019年以来24.7%的病例使用了非达霉素。总体死亡率和归因死亡率分别为11.3%和4.7%。诊断至死亡的中位时间为11天,复发率为4%。64%的复发病例使用了贝佐托昔单抗。多变量分析显示,只有血液透析与死亡率相关。在预测复发风险方面未发现具有统计学意义的关联关系。我们主张将CDI报告设为强制性,并建议在H-SDF中对CDI诊断进行编码,以协助监测感染率。应特别注意预防血液透析患者发生CDI。